Dacarbazine
Dacarbazine (dacarbazine) is a small molecule pharmaceutical. Dacarbazine was first approved as Dtic-dome on 1982-01-01. It is used to treat fibrosarcoma, hodgkin disease, islet cell carcinoma, medullary carcinoma, and melanoma amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Dacarbazine (discontinued: Dacarbazine, Dtic-dome)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aleve arthritis pain gel | ANDA | 2023-11-30 |
| amazon basic care arthritis pain | ANDA | 2024-05-17 |
| arthritis pain | ANDA | 2024-03-18 |
| arthritis pain reliever | ANDA | 2024-06-14 |
| arthritis pain relieving | ANDA | 2023-05-15 |
| arthrotec | New Drug Application | 2023-08-16 |
| aspercreme arthritis | ANDA | 2023-10-11 |
| basic care arthritis pain | ANDA | 2022-01-06 |
| bentyl | New Drug Application | 2024-04-03 |
| berkley and jensen arthritis pain | ANDA | 2023-07-26 |
Show 126 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neuroblastoma | EFO_0000621 | D009447 | — |
| hodgkin disease | — | D006689 | C81 |
| melanoma | — | D008545 | — |
| fibrosarcoma | — | D005354 | — |
| rhabdomyosarcoma | — | D012208 | — |
| islet cell carcinoma | — | D018273 | C25.4 |
| medullary carcinoma | — | D018276 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9130 | Dacarbazine, 100 mg |
Clinical
Clinical Trials
233 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 20 | 57 | 36 | 1 | 3 | 102 |
| Hodgkin disease | D006689 | — | C81 | 5 | 52 | 26 | 1 | 7 | 86 |
| Lymphoma | D008223 | — | C85.9 | 5 | 50 | 26 | 1 | 7 | 84 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | 2 | 1 | — | 5 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 3 | 9 | 8 | — | 1 | 18 |
| Leiomyosarcoma | D007890 | — | — | 1 | 4 | 5 | — | — | 9 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | — | 6 | 2 | — | — | 7 |
| Neoplasms | D009369 | — | C80 | 3 | 3 | 1 | — | — | 6 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | 1 | 4 | — | 1 | 6 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | 3 | 3 | — | — | 5 |
| Cutaneous malignant melanoma | D000096142 | — | — | — | 1 | 2 | — | — | 3 |
| Liposarcoma | D008080 | — | — | — | — | 3 | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 1 | 1 | — | — | 2 |
| T-cell lymphoma | D016399 | — | — | — | 1 | 1 | — | — | 2 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | — | — | — | 3 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | 1 | 3 |
| Immunotherapy | D007167 | — | — | 1 | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | — | 1 | 2 | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | 1 | — | — | — | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | — | — | — | 1 | 3 |
| Small cell carcinoma | D018288 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Carcinoid tumor | D002276 | — | D3A.00 | 1 | — | — | — | — | 1 |
| Parathyroid neoplasms | D010282 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dacarbazine |
| INN | dacarbazine |
| Description | Dacarbazine is a monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. It has a role as an antineoplastic agent, an alkylating agent, a prodrug and a carcinogenic agent. It is a monocarboxylic acid amide, a member of imidazoles and a triazene derivative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)/N=N/c1[nH]cnc1C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 1185241-28-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL476 |
| ChEBI ID | — |
| PubChem CID | 2942 |
| DrugBank | DB00851 |
| UNII ID | 7GR28W0FJI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,173 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arthrotec, Cambia, Capsinac, Cataflam, Clofenax, Dacarbazine, Dicloenac sodium and misoprostol, Diclofenac, Diclofenac epolamine, Diclofenac potassium, Diclofenac potassium for oral solution, Diclofenac sodium, Diclofenac sodium 1.5%, Diclofenac sodium and misoprostol, Diclofenac sodium d/r, Diclofenac sodium delayed release, Diclofenac sodium diclofenac sodium, Diclofenac sodium extended-release, Diclofenac sodium gel, Diclofenac sodium misoprostol, Diclofenac sodium topical sol, Diclofenac sodium topical solution, Diclofenac sodium/misoprostol, Diclogen, Diclosaicin, Diclostream, Diclotral pak, Diclovix, Diclovix cm, Diclovix m, Diclozor, Dimentho, Fenovar, Flector, Flexipak, Iclofenac cp, Inavix, Inflatherm, Lefluniclo, Lextol, Licart, Lixofen, Lofena, Pennsaid, Previdolrx analgesic pak, Previdolrx plus analgesic pak, Profinac, Solaravix, Varophen, Venngel one, Ziclopro, Zipsor, Zorvolex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
120,332 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use